title: [Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT -11 combination chemotherapy].
abstract: We describe a case of liver metastasis of colorectal cancer that became resectable after bevacizumab (Bmab), CPT-11, and S-1 ie Bmab+IRIS combination chemotherapy. A 65-year-old man experienced repeated constipation and diarrhea in August of 2013. Colonoscopy was conducted by a local doctor, and a tumor(diagnosed as adenocarcinoma tub1 by biopsy)was found in the upper rectum. Computed tomography performed at our institution detected synchronous liver metastasis. On September 9, laparoscopic rectal anterior resection was performed to prevent metastasis to the ileus, and on October 9, the patient began receiving Bmab+IRIS combination chemotherapy. Before chemotherapy, 3 metastases with a maximum diameter of 7 cm diameter)were observed in the right lobe of the liver. After 4 courses of chemotherapy, their maximum diameter was 3 cm, which allowed resection. Ultimately, the metastases were completely resected. Conversion of non optimal resection cases of liver metastases to optimal cases by using Bmab+IRIS chemotherapy is extremely rare. We suggest that Bmab+IRIS chemotherapy could be an option for conversion of non optimal liver resection cases to optimal cases. We report this rare case and discuss the implications of adjuvant chemotherapy for this patient.
authors.affiliation: Dept. of Clinical Oncology, Ishinomaki Red Cross Hospital.
authors.forename: Hiroo
authors.initials: H
authors.lastname: Imai
authors.forename: Kinya
authors.initials: K
authors.lastname: Sawada
authors.forename: Akehumi
authors.initials: A
authors.lastname: Sato
authors.forename: Kazuya
authors.initials: K
authors.lastname: Nishi
authors.forename: Takashi
authors.initials: T
authors.lastname: Sasaki
authors.forename: Toru
authors.initials: T
authors.lastname: Takahashi
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Ohori
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D012811:Sigmoid Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D000068258:Bevacizumab; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin